Subsequently, ALK inhibitor crizotinib was the first FDA-approved targeted therapy for the treatment of ALK-positive advanced NSCLC patients in 2011, the second generation ALK TKIs ceritinib, alectinib and ensartinib were all approved for metastatic ALK + NSCLC [21–26]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.